Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: T he EXAMINE trial
Diabetes Obesity and Metabolism2017Vol. 19(5), pp. 664–671
Citations Over TimeTop 10% of 2017 papers
Simon Heller, Richard M. Bergenstal, William B. White, Stuart Kupfer, George L. Bakris, William C. Cushman, Cyrus R. Mehta, Steven E. Nissen, Craig Wilson, Faı̈ez Zannad, Yuyin Liu, Noah M. Gourlie, Christopher P. Cannon, for the EXAMINE Investigators
Abstract
There were no relationships between baseline HbA1c levels or HbA1c levels after 1 month of treatment and the risk of MACE. Alogliptin improved glycaemic control without increasing hypoglycaemia. Reported events of hypoglycaemia and serious hypoglycaemia were associated with MACE. These data underscore the safety of alogliptin in improving glycaemic control in T2DM post-ACS. Further study of hypoglycaemia as an independent risk factor for MACE in patients with T2DM and coronary disease is needed.